Quest Diagnostics

Quest Diagnostics, founded in 1967, is a key player in the Biotechnology, Health Care, and IT sectors, headquartered in the United States. The company’s slogan, "Working together to create a healthier world, one life at a time," encapsulates its mission to empower individuals through comprehensive diagnostic insights.

As indicated by its extensive offerings, Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals nationwide. Notably, it maintains the widest test menu available with over 3,000 tests and leads in cancer diagnostics, enhanced by a dedicated team of approximately 900 M.D.s and Ph.D.s.

The firm reported 2020 revenue of $9.44 billion. Its expansive network includes around 2,250 patient service centers and laboratories in strategic global locations. Furthermore, Quest Diagnostics stands as a leading provider of pre-employment drugs-of-abuse screening and clinical trials testing. Recently, the company secured a Post Ipo Debt investment as of 01 August 2024. The absence of disclosed investors in this round might intrigue prospective stakeholders about future financial strategies.